Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Other Routine +

Red Light Holland Announces Filament Health's PEX010 Drug Candidate, the Standardized and Patented Natural Psilocybin Trusted Across 80+ Studies Globally, Selected by UCSF for Study Probing Preclinical Alzheimer's Markers

Red Light Holland Secures UCSF Supply Deal for PEX010, But Clinical Progress Remains Incremental Amid Dilution Concerns

By The Northwire Desk — AI Analysis Jun 04, 2026 · 07:32 TRIP · 0.035 Red Light Holland Corp.
Executive Summary
  • Red Light Holland announced a supply agreement with UCSF to provide its patented PEX010 botanical psilocybin for a double-blind trial on neuroinflammatory markers in older adults.
  • The deal follows the April 30, 2026 acquisition of Filament Health, which brought 76 patents and GMP manufacturing capabilities.
  • PEX010 is now utilized in over 80 global academic studies, reinforcing its position as a standardized, pharmaceutical-grade candidate.
  • The announcement aligns with a steady stream of clinical supply updates and partnership expansions throughout May 2026, including a microdose format launch in New Zealand and a JAMA-published cocaine use disorder study.
Material Impact
  • The UCSF supply agreement is a routine operational milestone rather than a material catalyst. Clinical supply agreements are expected given the company's stated strategy post-Filament acquisition.
  • The news does not introduce new pricing, revenue recognition, or regulatory approval milestones. It merely confirms ongoing demand for PEX010 in academic research.
  • Historical progression shows a pattern of incremental supply updates (UCalgary, UBC, Allu Therapeutics) that have not historically triggered sustained price appreciation, as evidenced by the stock consolidating between $0.03 and $0.04 following similar announcements in May.
  • The market has already priced in the Filament acquisition and the associated IP portfolio. This announcement serves as a follow-up validation rather than a paradigm shift.
TRIP · Price
Company Overview
  • Red Light Holland Corp. is a Canadian psychedelic medicine company focused on the development and commercialization of natural psilocybin products.
  • The flagship project is PEX010, a patented, GMP-compliant botanical psilocybin drug candidate.
  • The company recently completed the acquisition of Filament Health Corp., integrating its manufacturing facility, Health Canada Level 8 Dealer's Licence, and extensive patent portfolio.
  • PEX010 is authorized for clinical trials by the FDA and Health Canada, with ongoing studies targeting depression, PTSD, substance use disorders, and cancer-related distress.
Read the original news release →

More from Red Light Holland Corp.

Jun 18, 2026 · 09:02

Early-stage preclinical milestone adds to pipeline, but stock has already priced in a +200% run; execution risk remains high.

Other Jun 08, 2026 · 07:31

Red Light Holland's Wholly Owned Subsidiary, Filament Health, Signs Agreement to Supply PEX010 Botanical Psilocybin Drug Candidate for Study at GHU Paris Psychiatrie & Neurosciences in France

Other May 25, 2026 · 08:40

Red Light Holland Expands Filament Health Psychedelic Supply Footprint in New Zealand

Other May 14, 2026 · 08:31

Red Light Holland expands its clinical psilocybin network, but mounting share dilution and a transition to pharma leave investors waiting for a clear commercial catalyst.

Production / Operations May 13, 2026 · 09:13

Red Light Holland Consolidates Psychedelic Platform Post-Acquisition Amidst Management Transition

Financings May 08, 2026 · 07:31

Red Light Holland Validates Filament Acquisition with Cocaine Trial Data, Yet Dilution Risks Loom

Other